Axogen (Nasdaq:AXGN) announced today that it appointed Michael Dale, former SVP of Abbott’s Structural Heart unit, as its new CEO and board member. Dale’s appointment goes into effect tomorrow, Aug. 9, 2024. He succeeds Karen Zaderej, who intends to remain in an advisory role for nine months. Axogen also announced that it named Paul Thomas […]
AxoGen
Axogen launches Avive+ Soft Tissue Matrix
Axogen (Nasdaq:AXGN) today announced it has launched its Avive+ Soft Tissue Matrix. Avive+ is intended to be used as a soft tissue barrier. It is a resorbable and multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during peripheral nerve healing. “Product innovation is integral to our mission at Axogen,” CEO and President […]
Axogen announces first surgical implant of Avive+ Soft Tissue Matrix
Axogen (Nasdaq:AXGN) this week announced the first surgical implantation of its Avive+ Soft Tissue Matrix. Avive+ is a resorbable, multi-layer, placenta-based allograft that provides temporary protection and tissue separation during the critical phase of nerve healing. The soft tissue matrix is processed and distributed as a 361 tissue product in accordance with FDA Good Tissue Practices […]
Axogen has positive nerve implant data
Axogen (Nasdaq:AXGN) announced positive topline results from a clinical study evaluating its Axoguard Nerve Cap. The REPOSE study compares standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with the Axoguard Nerve Cap. Axoguard Nerve Cap is a proprietary surgical implant. Derived from porcine submucosal extracellular matrix remodeled during healing, […]
Axogen launches AxoGuard HA+ nerve protector
Axogen (Nasdaq:AXGN) announced today that it fully launched its Axoguard HA+ nerve protector for peripheral nerve injury protection. The company designed the proprietary device to provide both short- and long-term protection for those nerve injuries. It features a processed porcine submucosa extracellular matrix base layer with a hyaluronate-alginate gel coating. The gel facilitates enhanced nerve […]
Axogen appoints Jens Schroeder Kemp as chief marketing officer
Axogen today announced it appointed Jens Schroeder Kemp as chief marketing officer. Kemp has more than 20 years of strategic marketing, sales and business development experience in the medical device industry. He will report directly to CEO and President Karen Zaderej. “I am thrilled to welcome Jens to Axogen. His extensive strategic marketing experience and […]
AxoGen beats The Street in Q3 results
AxoGen (NSDQ:AXGN) posted third-quarter results today that beat the consensus forecast on Wall Street. The Alachua, Fla.-based company reported losses of -$6.1 million, or -14¢, on sales of $28.6 million for the three months ended Sept. 30, 2019, for a bottom-line gain of 26.4% sales growth of 26% compared with Q3 2018. Adjusted to exclude one-time […]
Axogen shares slip on expanded Avance nerve graft study
AxoGen (NSDQ:AXGN) today expanded a study of its Avance graft for treating peripheral nerve damage on a pre-specified statistical analysis, sending its share price down slightly today. Alachua, Fla.-based AxoGen is adding 50 patients and five new centers to the Recon study of Avance, a human allograft designed to bridge severed nerves without a second surgical […]
ReShape Lifesciences CEO Gladney to resign | Personnel Moves – January 29, 2019
ReShape Lifesciences (NSDQ:RSLS) said yesterday that its prez & CEO Dan Gladney will resign from his positions with the company, effective March 31. Gladney will remain with the company as board chair, San Clemente, Calif.-based ReShape Lifesciences said. The company’s board of directors said they will immediately begin to look for a replacement, according to an […]
Insulet taps former Medtronic finance exec McMillan as CFO | Personnel Moves – January 8, 2019
Insulet (NSDQ:PODD) said yesterday that it tapped former Medtronic minimally invasive therapies CFO and finance VP Wayde McMillan as its new chief financial officer, replacing Michael Levitz. The Acton, Mass.-based diabetes-focused medtech company said that McMillan will join the company in February and that Levitz will continue as an advisor for a period following the […]
AtriCure falls despite solid Q4, 2018 prelims | Wall Street Beat
AtriCure (NSDQ:ATRC) shares took a fall today despite preliminary results for the fourth quarter and 2018 that topped estimates. The Mason, Ohio-based cardiac implant maker said it expects to post Q4 sales of $52.9 million and 2018 sales of $201.6 million, beating the consensus estimatyes on Wall Street for both periods. “We are pleased with our […]
